Shree Parshwa Healthcare

Brand	Tacrolimus
Treatment	Kidney or liver transplant.
Prescription/Non prescription	Prescription
Packaging Size	50 Capsules
Dose Strength	0.5 mg
Manufacturer	Astellas

Product Type:

• POM
• Once only
• Prolonged release hard capsules

Brand	Advagraf
Treatment	Medications to prevent rejection of a kidney, heart, or liver transplant
Prescription/Non prescription	Prescription
Packaging Size	5x10 Prolonged release hard capsules(Once Daily)
Dose Strength	1 mg
Manufacturer	Astellas

Regorafenib is an oral multikinase inhibitor used to treat certain types of advanced cancers, including colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (liver cancer). It is available in a tablet form, often under the brand name Stivarga. 

Prescription/Non prescription	Prescription
Packaging Size	100 capsules(10x10)
Brand	Prograf
Usage/Application	Analgesics
Treatment	Medications to prevent rejection of a kidney, heart, or liver transplant
Manufactured By	Pancea Biotech
Packaging Type	Box
Strength	0.5 mg
Dose Strength	1 mg

Product Details:

• Prograf capsules are not filled to maximum capsules capacity capsule contains labeled amount.
• This package for households without young children 
• NDC 0469-0617-11

Packaging type	Box
Dosage	500 mg
Brand Name	MMF
Treatment	Body rejecting an organ (such as a kidney, heart or liver) after a transplant
Packaging Size	60 Tablets
Type Of Medicines	USP
Manufacturer By	Ipca Laboratories Ltd.

Mycophenolate Mofetil Tablets USP 500 mg, commonly abbreviated as MMF 500 mg, are a medication used primarily in immunosuppressive therapy to prevent rejection of transplanted organs and to treat certain autoimmune diseases. Here’s a detailed description:
1. **Active Ingredient**: Mycophenolate Mofetil (MMF) is the active pharmaceutical ingredient. It is a prodrug that is converted in the body to mycophenolic acid (MPA). MPA inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme crucial for the proliferation of T and B lymphocytes. By suppressing the immune response, MMF helps prevent rejection of transplanted organs (e.g., kidney, heart, liver) and is also used in the treatment of autoimmune diseases such as lupus nephritis and rheumatoid arthritis.
2. **Dosage Strength**: MMF tablets are typically available in strengths of 500 mg. The dosage may vary depending on the specific transplant type, the patient's weight, kidney function, and other medical conditions. It is usually taken orally twice daily, with or without food, as directed by a healthcare provider.
3. **Indications**:   - **Organ Transplantation**: MMF is used in combination with other immunosuppressive medications (e.g., corticosteroids, calcineurin inhibitors) to prevent rejection of transplanted organs.   - **Autoimmune Diseases**: It is also used to treat autoimmune conditions where the immune system attacks healthy tissues, such as systemic lupus erythematosus (SLE) and other autoimmune diseases.
4. **Formulation**: MMF tablets may be formulated as immediate-release or may have a special coating to control the release of the medication over time. This helps ensure optimal absorption and effectiveness.
5. **Monitoring**: Regular monitoring of kidney function, blood counts (especially white blood cell counts), and other parameters is crucial during treatment with MMF to assess effectiveness and manage potential side effects.
6. **Side Effects**: Common side effects may include gastrointestinal disturbances (nausea, vomiting, diarrhea), infections (due to suppressed immune function), and an increased risk of certain cancers (especially skin cancer and lymphoma).
7. **Precautions**: It is important to inform healthcare providers about any pre-existing medical conditions, allergies, or other medications being taken, as interactions can occur. Pregnant women should avoid MMF due to potential harm to the fetus.
MMF 500 mg tablets are essential in the management of transplant recipients and patients with autoimmune diseases, helping to suppress immune activity and maintain the health of transplanted organs. Close monitoring and adherence to prescribed dosages are critical for optimizing treatment outcomes and minimizing potential complications.

Manufacturer	Dr. Reddy's
Treatment	Kidney, heart, or liver transplant.
Prescription/Non prescription	Prescription
Brand	Tacrolim
Packaging Size	3 blister x 10 capsules each per blister
Dose Strength	0.5 mg, 1 mg

Regorafenib is an oral multikinase inhibitor used to treat certain types of advanced cancers, including colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (liver cancer). It is available in a tablet form, often under the brand name Stivarga. 

Packaging type	Box
Packaging Size	3 x 10 Delayed Release Tablets
Brand Name	Biomyf S
Dose/Strength	360 mg
Brand	Alniche Life Sciences Pvt. Ltd.
Type Of Medicines	Allopathic
Treatment	Keep the body from harming the organ after an organ transplant

Biomyf-S 360 Mycophenolic Acid Delayed Release Tablets USP are a medication used in immunosuppressive therapy to prevent organ rejection following transplant surgeries. Here’s a detailed description of these tablets:
1. **Active Ingredient**: Biomyf-S 360 tablets contain Mycophenolic Acid as the active pharmaceutical ingredient. Mycophenolic Acid is the active form of mycophenolate mofetil (MMF), which is a prodrug converted to mycophenolic acid in the body. Mycophenolic acid works by inhibiting the enzyme inosine monophosphate dehydrogenase (IMPDH), which is crucial for the synthesis of guanosine nucleotides. By blocking this enzyme, mycophenolic acid suppresses the proliferation of T and B lymphocytes, key cells involved in the immune response. This immunosuppressive action helps prevent rejection of transplanted organs (e.g., kidney, heart, liver) and is also used to treat autoimmune diseases such as lupus nephritis.
2. **Delayed Release Formulation**: The tablets are formulated as delayed-release, which means they are designed to release the medication gradually over time rather than immediately upon ingestion. This formulation helps to ensure sustained therapeutic levels of mycophenolic acid in the bloodstream, optimizing its effectiveness and reducing the frequency of dosing.
3. **Indications**: Biomyf-S 360 tablets are indicated for:   - **Organ Transplantation**: Used in combination with other immunosuppressive medications to prevent rejection of transplanted organs.   - **Autoimmune Diseases**: Used to treat autoimmune conditions where the immune system attacks healthy tissues, such as systemic lupus erythematosus (SLE) and other forms of lupus nephritis.
4. **Dosage**: The dosage of Biomyf-S 360 tablets depends on factors such as the specific transplant type, the patient's weight, kidney function, and other medical conditions. It is typically taken orally twice daily, with or without food, as directed by a healthcare provider.
5. **Monitoring**: Regular monitoring of kidney function, blood counts, and other parameters is essential during treatment with Biomyf-S 360 tablets to ensure effectiveness and manage potential side effects.
6. **Side Effects**: Common side effects may include gastrointestinal disturbances (nausea, vomiting, diarrhea), infections, and an increased risk of certain cancers (especially skin cancer and lymphoma) due to the immunosuppressive effects of the medication.
7. **Precautions**: It is important to inform healthcare providers about any pre-existing medical conditions, allergies, or other medications being taken, as interactions can occur. Pregnant women should avoid Biomyf-S 360 tablets due to potential harm to the fetus.
Biomyf-S 360 Mycophenolic Acid Delayed Release Tablets USP are an integral part of immunosuppressive therapy regimens for preventing organ rejection and managing autoimmune diseases effectively. Close monitoring and adherence to prescribed dosages are crucial for optimizing treatment outcomes and minimizing potential complications.

Treatment	Attacking and rejecting your transplanted organ (such as kidney, liver, heart)
Packaging Size	6 x 10 Tablets
Brand	Mycept S
Manufacturer By	Panacea Biotec (innovation in support of life)
Dosage	360 mg

Mycept-S 360 Mycophenolate Sodium Enteric Coated Tablets are a medication primarily used in immunosuppressive therapy to prevent organ rejection in transplant recipients and to treat certain autoimmune conditions. Here's a detailed description of Mycept-S 360 tablets:

1. Active Ingredient: Mycept-S 360 tablets contain Mycophenolate Sodium as the active pharmaceutical ingredient. Mycophenolate Sodium is a prodrug of mycophenolic acid, which is an immunosuppressant. It inhibits the proliferation of T and B lymphocytes by blocking an enzyme called inosine monophosphate dehydrogenase (IMPDH). This enzyme is crucial for the synthesis of guanosine nucleotides, which are necessary for DNA and RNA synthesis in cells involved in the immune response. By inhibiting this enzyme, Mycophenolate Sodium reduces the activity of the immune system, thereby preventing rejection of transplanted organs (e.g., kidney, heart, liver) and treating certain autoimmune diseases.

2. Enteric Coating: The tablets are enteric-coated, which means they have a special coating that allows them to pass through the stomach without being dissolved by stomach acid. The coating helps the tablets to dissolve in the intestine instead, which can reduce gastrointestinal side effects such as nausea and stomach upset.

3. Indications: Mycept-S 360 tablets are indicated for:

   • Organ Transplantation: Used in combination with other immunosuppressive medications to prevent rejection of transplanted organs.
   • Autoimmune Diseases: Used to treat autoimmune conditions where the immune system attacks healthy tissues, such as systemic lupus erythematosus (SLE) and lupus nephritis.

4. Dosage: The dosage of Mycept-S 360 tablets depends on factors such as the specific transplant type, the patient's weight, kidney function, and other medical conditions. It is typically taken orally twice daily, with or without food, as directed by a healthcare provider.

5. Monitoring: Regular monitoring of kidney function, blood counts, and other parameters is important during treatment with Mycept-S 360 tablets to ensure effectiveness and manage potential side effects.

6. Side Effects: Common side effects may include gastrointestinal disturbances (nausea, vomiting, diarrhea), infections, and an increased risk of certain cancers (especially skin cancer and lymphoma) due to the immunosuppressive effects of the medication.

7. Precautions: It's crucial to inform healthcare providers about any pre-existing medical conditions, allergies, or other medications being taken, as interactions can occur. Pregnant women should avoid Mycept-S 360 tablets due to potential harm to the fetus.

Mycept-S 360 Mycophenolate Sodium Enteric Coated Tablets play a vital role in preventing organ rejection after transplantation and managing autoimmune diseases effectively. Close monitoring and adherence to prescribed dosages are essential for optimizing treatment outcomes and minimizing potential complications.

Treatment	Attacking and rejecting your transplanted organ (such as kidney, liver, heart).
Packaging Size	5 x 10 tablets
Packaging Type	Box
Brand	Biomyf
Dose	500 mg
Manufacturer By	Alniche Life Sciences Pvt. Ltd.

Biomyf-500 is a medication that contains mycophenolate mofetil as its active ingredient. Here's a detailed description:
1. **Active Ingredient**: Mycophenolate mofetil (MMF) is a prodrug of mycophenolic acid (MPA). Mycophenolic acid inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for the synthesis of guanosine nucleotides. By blocking this enzyme, mycophenolic acid suppresses the proliferation of T and B lymphocytes, key cells involved in the immune response. This immunosuppressive action helps prevent rejection of transplanted organs (e.g., kidney, heart, liver) and is also used to treat autoimmune diseases such as lupus nephritis.
2. **Indications**:   - **Organ Transplantation**: Biomyf-500 is used in combination with other immunosuppressive medications to prevent rejection of transplanted organs.   - **Autoimmune Diseases**: It is also used to treat autoimmune conditions where the immune system attacks healthy tissues, such as systemic lupus erythematosus (SLE) and lupus nephritis.
3. **Dosage**: Biomyf-500 tablets are typically available in 500 mg strength. The dosage and frequency depend on factors such as the specific transplant type, the patient's weight, kidney function, and other medical conditions. It is usually taken orally twice daily, with or without food, as directed by a healthcare provider.
4. **Formulation**: Biomyf-500 tablets are formulated for oral administration. They may be in immediate-release form or may have a special coating to control the release of the medication over time, ensuring optimal absorption and effectiveness.
5. **Monitoring**: Regular monitoring of kidney function, blood counts, and other parameters is important during treatment with Biomyf-500 to ensure effectiveness and manage potential side effects.
6. **Side Effects**: Common side effects may include gastrointestinal disturbances (nausea, vomiting, diarrhea), infections, and an increased risk of certain cancers (especially skin cancer and lymphoma) due to the immunosuppressive effects of the medication.
7. **Precautions**: It's essential to inform healthcare providers about any pre-existing medical conditions, allergies, or other medications being taken, as interactions can occur. Pregnant women should avoid Biomyf-500 tablets due to potential harm to the fetus.
Biomyf-500 plays a critical role in immunosuppressive therapy for preventing organ rejection and managing autoimmune diseases effectively. Close monitoring and adherence to prescribed dosages are crucial for optimizing treatment outcomes and minimizing potential complications.

Packaging Size	6x10 Tablets
Packaging Type	Box
Dose/Strength	360 mg
Brand	Mycept S
Type Of Medicines	Allopathic
Treatment	Transplanted organ (such as kidney,liver,heart)

Mycept-S 360 Mycophenolic Acid Delayed Release Tablets USP are a specific formulation of medication used in immunosuppressive therapy, primarily for preventing organ rejection in transplant recipients and treating certain autoimmune diseases. Here's a detailed description of Mycept-S 360 tablets:
1. **Active Ingredient**: Mycept-S 360 tablets contain Mycophenolic Acid as the active pharmaceutical ingredient. Mycophenolic Acid (MPA) is the active form of mycophenolate mofetil (MMF), a prodrug that is converted to MPA in the body. MPA inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for the synthesis of guanosine nucleotides. By blocking this enzyme, MPA suppresses the proliferation of T and B lymphocytes, key cells involved in the immune response. This immunosuppressive action helps prevent rejection of transplanted organs (e.g., kidney, heart, liver) and is also used to treat autoimmune diseases such as lupus nephritis and rheumatoid arthritis.
2. **Delayed Release Formulation**: The tablets are formulated as delayed-release, which means they are designed to release the medication gradually over time rather than immediately upon ingestion. This formulation helps to ensure sustained therapeutic levels of Mycophenolic Acid in the bloodstream, optimizing its effectiveness and reducing the frequency of dosing.
3. **Indications**: Mycept-S 360 tablets are indicated for:   - **Organ Transplantation**: Used in combination with other immunosuppressive medications to prevent rejection of transplanted organs.   - **Autoimmune Diseases**: Used to treat autoimmune conditions where the immune system attacks healthy tissues, such as systemic lupus erythematosus (SLE) and lupus nephritis.
4. **Dosage**: The dosage of Mycept-S 360 tablets depends on factors such as the specific transplant type, the patient's weight, kidney function, and other medical conditions. It is typically taken orally twice daily, with or without food, as directed by a healthcare provider.
5. **Monitoring**: Regular monitoring of kidney function, blood counts, and other parameters is important during treatment with Mycept-S 360 tablets to ensure effectiveness and manage potential side effects.
6. **Side Effects**: Common side effects may include gastrointestinal disturbances (nausea, vomiting, diarrhea), infections (due to suppressed immune function), and an increased risk of certain cancers (especially skin cancer and lymphoma).
7. **Precautions**: It is important to inform healthcare providers about any pre-existing medical conditions, allergies, or other medications being taken, as interactions can occur. Pregnant women should avoid Mycept-S 360 tablets due to potential harm to the fetus.
Mycept-S 360 Mycophenolic Acid Delayed Release Tablets USP are an integral part of immunosuppressive therapy regimens for preventing organ rejection and managing autoimmune diseases effectively. Close monitoring and adherence to prescribed dosages are crucial for optimizing treatment outcomes and minimizing potential complications.